Latest total liabilities for DICE: $32M.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
As of the most recent data (June 2023), DICE shows a total liabilities of $32M. That compares with $25M in the prior-year period — up 28.3% year over year. Scroll down for historical charts and peer comparison views.
Compared with the year-ago period, DICE's total liabilities is now $32M (was $25M) — a 28.3% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether DICE Therapeutics is outperforming or lagging.
Tracking DICE's total liabilities over time shows whether DICE Therapeutics is scaling, shrinking, or reshaping that part of the business. The current reading is $32M That compares with $25M in the prior-year period — up 28.3% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.
Besides this total liabilities page, Stockcircle has DICE Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect total liabilities (currently $32M) with ownership activity and broader fundamentals.
DICE Therapeutics's total liabilities is $32M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.